Nabla Bio
Predicts and designs novel biological sequences with high accuracy.. [Contact for Pricing]
Last verified:
What is Nabla Bio?
Nabla Bio is a biotechnology company that uses AI to design antibodies for intractable diseases. The platform combines de novo drug design with large-scale, human-relevant testing to turn trial-and-error discovery into designable, engineerable success. At its core is JAM (Joint Atomic Model), a multimodal generative modeling system trained on massive protein sequence and structure data, strengthened with Nabla-generated, human-relevant measurements.
Key features include generative molecular design that can autocomplete partial molecular context for de novo biologics design, epitope scaffolding, developability and affinity optimization, and parallel de novo antibody design across multiple targets simultaneously. The platform also enables generative design of multispecifics, tackling the hard problem of creating antibodies that engage multiple disease pathways while preserving individual target affinities. Nabla Bio specializes in drugging hard targets like GPCRs, ion channels, and transporters that are notoriously difficult to access with conventional methods.
The platform is designed for pharmaceutical and biotech companies seeking to design drugs against complex disease targets. Nabla Bio partners with leading pharmaceutical companies including Takeda to bring antibody therapies to patients. The company integrates AI-guided design with wet-lab driven measurement, producing thousands of protein designs in mammalian systems and measuring binding, developability properties, and function in cellular and in vivo contexts.
Nabla Bio was founded in 2020 by Frances Anastassacos and Surge Biswas, AI and protein design experts from Harvard University. The company is well-funded with over $37M raised, revenue-generating, and based in Boston/Cambridge with 8 employees. Their mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients by designing antibodies that precisely bind disease targets while minimizing manufacturability and toxicity risks.
Nabla Bio pricing
Pricing model: Freemium
Nabla Bio does not offer public pricing, free tiers, or self-service plans. The platform is accessed through partnerships and collaborations with pharmaceutical companies. The company operates on a business model involving licensing agreements, partnerships, and collaborative projects. Notable collaborations include a second multi-year research partnership with Takeda worth double-digit millions in upfront and research cost payments, with potential success-based payments exceeding $1 billion. Interested parties must contact [email protected] for molecule development partnerships or accessing JAM-2.
Nabla Bio pros
- Atomic precision antibody design using AI
- JAM multimodal generative modeling system
- De novo antibody design from scratch
- Parallel design campaigns for multiple targets simultaneously
- High hit rates on soluble targets
- Epitope-precise design specifies binding site upfront
- Drugs hard targets like GPCRs and ion channels
- Generative design of multispecific architectures
- Human-relevant data generation at scale in mammalian systems
- Measures binding, developability, and cellular function
- Eliminates need for iterative lab-in-the-loop screening
- Superior manufacturability, safety, and efficacy
- Double-digit hit rates validated in non-human primates
- Picomolar binding with strong pK and low immunogenicity
- Founded by Harvard protein language modeling pioneers
- Well-funded with $37M+ raised and revenue-generating
- Active collaborations with major pharmaceutical companies like Takeda
Nabla Bio cons
- Primarily accessible only to large pharmaceutical companies
- Not available as self-service software for individual researchers
- Requires partnership or collaboration to access platform
- Steep learning curve for unfamiliar users
- High resource intensity needed for integrated AI and wet-lab
- Limited accessibility for smaller biotech startups
- Dependence on data quality for accurate outcomes
- No public pricing or free tier available